- Home
- PK vs JANX Comparison
PK vs JANX Comparison
Compare PK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- JANX
- Stock Information
- Founded
- PK 1946
- JANX 2017
- Country
- PK United States
- JANX United States
- Employees
- PK N/A
- JANX N/A
- Industry
- PK Real Estate Investment Trusts
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- JANX Health Care
- Exchange
- PK Nasdaq
- JANX Nasdaq
- Market Cap
- PK 3.0B
- JANX 3.6B
- IPO Year
- PK N/A
- JANX 2021
- Fundamental
- Price
- PK $15.28
- JANX $58.54
- Analyst Decision
- PK Buy
- JANX Strong Buy
- Analyst Count
- PK 13
- JANX 11
- Target Price
- PK $18.79
- JANX $83.09
- AVG Volume (30 Days)
- PK 2.8M
- JANX 1.6M
- Earning Date
- PK 10-29-2024
- JANX 11-06-2024
- Dividend Yield
- PK 6.50%
- JANX N/A
- EPS Growth
- PK N/A
- JANX N/A
- EPS
- PK 1.57
- JANX N/A
- Revenue
- PK $2,662,000,000.00
- JANX $13,049,000.00
- Revenue This Year
- PK N/A
- JANX $40.27
- Revenue Next Year
- PK $4.04
- JANX N/A
- P/E Ratio
- PK $9.83
- JANX N/A
- Revenue Growth
- PK N/A
- JANX 54.12
- 52 Week Low
- PK $13.24
- JANX $7.79
- 52 Week High
- PK $18.05
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- PK 55.48
- JANX 55.16
- Support Level
- PK $15.19
- JANX $58.96
- Resistance Level
- PK $15.68
- JANX $66.34
- Average True Range (ATR)
- PK 0.35
- JANX 5.13
- MACD
- PK -0.06
- JANX 0.10
- Stochastic Oscillator
- PK 25.36
- JANX 61.47
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 23,428 rooms across 39 hotels in the United States. Park also has interests through joint ventures in another 2,665 rooms in four U.S. hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality U.S. hotels to focus on high-quality assets in domestic gateway markets.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.